Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach

Launched by PEKING UNIVERSITY CANCER HOSPITAL & INSTITUTE · May 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for a specific type of stomach cancer called hepatoid adenocarcinoma. The treatment combines three main medications: Disitamab Vedotin (RC48), a chemotherapy regimen known as SOX (which includes Oxaliplatin, Tegafur, Gimeracil, and Oteracil Potassium Capsules), and Sindillimab. The goal is to see how well this combination works before and after surgery, and to understand how safe it is for patients.

To participate in this trial, patients need to have a confirmed diagnosis of hepatoid adenocarcinoma that expresses a protein called HER2, and they should be in clinical stages II-III of the disease. They should also be generally healthy enough to tolerate surgery and treatment. Participants can expect to receive four cycles of the treatment before surgery, followed by surgery, and then an additional four cycles of treatment afterward. The trial is not yet recruiting patients, so if you or a loved one are interested, it’s important to stay informed about when it will begin.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The histological type of gastric hepatoid adenocarcinoma was confirmed by pathological biopsy；
• • HER2 expression (Immunohistochemistry: 1+,2+,3+);
• • Patients with clinical stage II-III;
• • Those who are expected to complete R0 excision;
• • ECOG score 0\~1;
• • Generally in good condition, perioperative treatment and surgical resection can be tolerated;
• • Patients were enrolled voluntarily.
• Exclusion Criteria:
• • Combined with other malignant tumors (excluding thyroid papillary carcinoma, facial basal cell carcinoma and other low-grade malignant tumors); -Patients with obstruction, bleeding, etc. who need surgical intervention after evaluation by clinicians;
• • dMMR/MSIH status；
• • Received other anti-tumor therapy before enrollment.